Biogen (NASDAQ:BIIB) Sets New 12-Month High Following Earnings Beat

Biogen Inc. (NASDAQ:BIIB)’s share price reached a new 52-week high during trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $195.96 and last traded at $194.6910, with a volume of 237889 shares. The stock had previously closed at $185.36.

The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.27. The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BIIB shares. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Biogen in a report on Tuesday, January 13th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. Morgan Stanley lifted their price objective on shares of Biogen from $149.00 to $156.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Guggenheim increased their price objective on shares of Biogen from $165.00 to $185.00 in a research report on Friday, October 31st. Finally, Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Eleven investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $192.58.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 748 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $179.30, for a total transaction of $134,116.40. Following the sale, the insider owned 6,271 shares in the company, valued at approximately $1,124,390.30. This trade represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Biogen

Several large investors have recently added to or reduced their stakes in BIIB. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Biogen during the fourth quarter valued at $3,321,000. HighTower Advisors LLC grew its holdings in shares of Biogen by 18.2% during the 4th quarter. HighTower Advisors LLC now owns 11,959 shares of the biotechnology company’s stock valued at $2,105,000 after acquiring an additional 1,843 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of Biogen during the fourth quarter worth $291,000. Mission Wealth Management LP boosted its position in Biogen by 5.3% during the fourth quarter. Mission Wealth Management LP now owns 1,822 shares of the biotechnology company’s stock valued at $321,000 after purchasing an additional 92 shares during the last quarter. Finally, Gabelli Funds LLC grew its stake in Biogen by 9.2% in the fourth quarter. Gabelli Funds LLC now owns 15,400 shares of the biotechnology company’s stock valued at $2,710,000 after purchasing an additional 1,300 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Stock Up 4.0%

The stock has a market cap of $28.28 billion, a price-to-earnings ratio of 17.66, a P/E/G ratio of 1.56 and a beta of 0.16. The business has a fifty day moving average of $176.55 and a 200 day moving average of $156.12. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.72 and a quick ratio of 2.04.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.